Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 6/20 | 0.55 |
| ▸ | ESR1 | P03372 | 11/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21526716 | 0.85 | ESR2 (0.50) | ESRRAESR1ESR2GAARAB9A | |
| SCHEMBL21526698 | 0.85 | ESRRA (0.61) | ESRRAESR1ESR2 | |
| SCHEMBL14085381 | 0.72 | CYP11B1 (0.49) | GAARAB9AALDH1A1L3MBTL1HTT | |
| SCHEMBL2589588 | 0.71 | ESRRA (1.00) | ESRRAESR1ESR2 | |
| SCHEMBL15006807 | 0.71 | ESR2 (0.74) | ESRRAESR1ESR2 | |
| SCHEMBL21526692 | 0.69 | ESR2 (0.57) | ESRRAESR1ESR2 | |
| SCHEMBL21526708 | 0.69 | ESR2 (0.57) | ESRRAESR1ESR2 | |
| SCHEMBL21526728 | 0.69 | ESR2 (0.49) | ESRRAESR1ESR2 | |
| SCHEMBL2006727 | 0.69 | CYP19A1 (0.48) | ESR1ESR2CA12CA9 | |
| SCHEMBL2584319 | 0.68 | ESR2 (1.00) | ESRRAESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640469-B2 | Polyhydroxyphthalazinone compound, preparation method thereof and use thereof | REJUVGEN PHARMACEUTICALS, INC. (CN) | 2020-05-05 | — | — | US | disclosed |
| US-10640469-B2 | Polyhydroxyphthalazinone compound, preparation method thereof and use thereof | REJUVGEN PHARMACEUTICALS, INC. (CN) | 2020-05-05 | — | — | US | disclosed |
| EP-3564215-A1 | POLYHYDROXYPHTHALAZINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Rejuvgen Pharmaceuticals, Inc. (CN) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564215-A1 | POLYHYDROXYPHTHALAZINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Rejuvgen Pharmaceuticals, Inc. (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640469-B2 | Polyhydroxyphthalazinone compound, preparation method thereof and use thereof | ESRRB, ESR2, ESRRA | ESRRA 3/4885ESR1 6/4885ESR2 2/4885 |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ESRRA 2081/4885ESR1 1678/4885ESR2 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.